Harris Geriatric Chest Disease

1. Auflage 2013
ISBN: 978-1-4831-8339-8
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 150 Seiten, Web PDF

Geriatric Chest Disease presents a guide to the management of chest disease in the elderly. It discusses the treatment and multiple pathology of the said disease. It addresses the normal changes in the aging lung. Some of the topics covered in the book are the symptoms of dyspnoea; cough; haemoptysis; the physical signs of diffuse airways obstruction; bronchography; bronchial carcinoma; the pneumonias; pulmonary tuberculosis; pulmonary thrombo-embolic disease; pleural effusion; fungal infection; and systemic lupus erythematosus. The symptomatic management of fractured ribs and hiatus hernia are covered. The respiratory disease associated with other systemic diseases is discussed. The text describes the adverse effects of drugs. A study of the exercise ventilation, heart-rate and electrocardiogram is presented. A chapter is devoted to the arterial blood gases and rheumatoid disease. Another section focuses on the functional effects and treatment of diffuse fibrosing alveolitis. The book can provide useful information to scientists, doctors, students, and researchers.

Autoren/Hrsg.

Harris, Luke

Inhaltsverzeichnis

1;Front Cover;1
2;Geriatric Chest Disease;4
3;Copyright Page;5
4;Table of Contents;10
5;Dedication;6
6;PREFACE;8
7;Section I: Principles of Diagnosis;14
7.1;Chapter One. Normal Changes in the Ageing Lung;16
7.1.1;1. ANATOMICAL CHANGES;16
7.1.2;2. PHYSIOLOGICAL CHANGES;16
7.2;Chapter Two. Symptoms;20
7.2.1;DYSPNOEA;20
7.2.2;COUGH;24
7.2.3;HAEMOPTYSIS;26
7.2.4;CHEST PAIN;27
7.2.5;SPUTUM;31
7.3;Chapter Three. Physical Signs;34
7.3.1;MAIN PHYSICAL SIGNS—CLINICAL CAUSES;34
7.3.2;1. IMPAIRED PERCUSSION;34
7.3.3;2. BRONCHIAL BREATHING;34
7.3.4;3. CRACKLES (crepitations);35
7.3.5;4. WHEEZING;35
7.3.6;5. DIFFUSE AIRWAYS OBSTRUCTION;36
7.4;Chapter Four. Laboratory Evaluation;38
7.4.1;1. CHEST X-RAY;38
7.4.2;2. BRONCHOGRAPHY;40
7.4.3;3. TOMOGRAPHY;40
7.4.4;4. SPUTUM;41
7.4.5;5. SKIN TESTS;41
7.4.6;6. LARYNGOSCOPY;42
7.4.7;7. BRONCHOSCOPY;42
7.4.8;8. BIOPSY;42
7.4.9;9. SEROLOGY AND BIOCHEMISTRY;43
7.4.10;10. ELECTROCARDIOGRAPHY;45
7.4.11;11. ANGIOGRAPHY;45
7.4.12;12. LUNG SCANNING;46
7.4.13;13. RESPIRATORY FUNCTION TESTS;46
8;Section 2: Specific Diseases;56
8.1;Chapter Five. Chronic Airways Obstruction;58
8.1.1;1. SMOKING;63
8.1.2;2. AIR POLLUTION;63
8.1.3;3· INFECTION;63
8.1.4;4. BRONCHOSPASM;64
8.1.5;5. MUCOSAL OEDEMA;67
8.1.6;6. SECRETIONS;67
8.1.7;7. UNDERVENTILATION;68
8.1.8;8· RIGHT-SIDED HEART FAILURE (COR PULMONALE);70
8.2;Chapter Six. Bronchial Carcinoma;72
8.2.1;PRESENTATION;72
8.2.2;COMMON PHYSICAL FINDINGS;73
8.2.3;IMPORTANT X-RAY FINDINGS;73
8.2.4;COMPLICATIONS;73
8.2.5;DIAGNOSIS;75
8.2.6;DIFFERENTIAL DIAGNOSIS;75
8.2.7;TREATMENT;76
8.3;Chapter Seven. The Pneumonias;79
8.3.1;PREDISPOSING FACTORS;79
8.3.2;CLINICAL FEATURES;80
8.3.3;DIFFERENTIAL DIAGNOSIS;81
8.3.4;PREVENTION;82
8.3.5;TREATMENT;82
8.3.6;COMPLICATIONS;83
8.3.7;PROGNOSIS;84
8.3.8;SEQUELAE;84
8.4;Chapter Eight. Pulmonary Tuberculosis;85
8.4.1;MILIARY TUBERCULOSIS;85
8.4.2;POST-PRIMARY PULMONARY TUBERCULOSIS;87
8.5;Chapter Nine. Pulmonary Thrombo-embolic Disease;93
8.5.1;AETIOLOGY;93
8.5.2;PREDISPOSING FACTORS;93
8.5.3;PATHOLOGY;94
8.5.4;CLINICAL EFFECTS;94
8.5.5;SPECIAL INVESTIGATIONS;95
8.5.6;DIAGNOSIS;96
8.5.7;DIFFERENTIAL DIAGNOSIS;97
8.5.8;PROGNOSIS;98
8.5.9;TREATMENT;98
8.6;Chapter Ten. Pleural Effusion;100
8.6.1;PATHOLOGY;100
8.6.2;CLINICAL FINDINGS;100
8.6.3;CHEST X-RAY;101
8.6.4;INVESTIGATION;101
8.6.5;TREATMENT;103
8.7;Chapter Eleven. Fungal Infection;104
8.7.1;ASPERGILLOSIS;104
8.7.2;CANDIDIASIS (MONILIASIS);106
8.8;Chapter Twelve. Some Less Common Diseases;107
8.8.1;1. BRONCHIECTASIS;107
8.8.2;2. SARCOIDOSIS;108
8.8.3;3. SPONTANEOUS PNEUMOTHORAX;108
8.8.4;4. DIFFUSE FIBROSING ALVEOLITIS;109
8.8.5;5. RHEUMATOID DISEASE;110
8.8.6;6. SYSTEMIC LUPUS ERYTHEMATOSUS;111
8.8.7;7. SYSTEMIC SCLEROSIS;111
9;Section 3: Special Problems;112
9.1;Chapter Thirteen. Symptomatic Management;114
9.1.1;1. HAEMOPTYSIS;114
9.1.2;2. DYSPNOEA;114
9.1.3;3. COUGH;116
9.1.4;4. EXPECTORATION;116
9.1.5;5. CHEST PAIN;117
9.2;Chapter Fourteen. Respiratory Disease associated with other Systemic Diseases;120
9.2.1;1. RESPIRATORY AND CARDIAC DISEASE;120
9.2.2;2. RESPIRATORY AND CEREBROVASCULAR DISEASE;123
9.2.3;3. RESPIRATORY DISEASE AND MENTAL STATE;125
9.2.4;4. RESPIRATORY AND NEUROLOGICAL DISEASE;125
9.2.5;5. RESPIRATORY AND GASTROINTESTINAL DISEASE;126
9.2.6;6. RESPIRATORY AND SKELETAL DISEASE;126
9.2.7;7· RESPIRATORY AND ENDOCRINE DISEASE;127
9.2.8;8. RESPIRATORY DISEASE AND ANAEMIA;127
9.3;Chapter Fifteen. Adverse Effects of Drugs;128
9.3.1;1. GENERAL;128
9.3.2;2. ANTIMICROBIALS;128
9.3.3;3. BRONCHODILATORS;129
9.3.4;4. CORTICOSTEROIDS;129
9.3.5;5. PHENOTHIAZINES;130
9.3.6;6· BENZODIAZEPINES;130
9.3.7;7. TRICYCLIC ANTI-DEPRESSANTS;130
9.3.8;8. DIURETICS;131
9.3.9;9. OPIATES, BARBITURATES AND OTHER HYPNOTICS;131
9.3.10;10. ß-ADRENERGIC BLOCKERS;131
9.3.11;11. DIGOXIN;132
9.3.12;12. á-METHYL DOPA;132
9.3.13;13. CARBENOXOLONE AND PHENYL-BUTAZONE;132
9.3.14;14. DRUG INTERACTIONS;132
10;Appendix A .Diagnosis of 500 consecutive Hospital Cases;134
11;Appendix B. Selected Bibliography;135
12;Index;138